A randomised controlled trial published in Clinical Infectious Diseases demonstrated that Thymosin Alpha-1 treatment in severe COVID-19 patients reduced 28-day mortality by 30% compared to standard care alone.17 While this was acute disease, not long COVID, it confirms the biological plausibility of the immune mechanism
The nasal format enables easy administration without injections or preparation, making it practical for structured wellness routines
BPC-157 and Thymosin Beta 4 emerged as important subjects of investigation due to their unique peptide structures and broad relevance within experimental biological research
This selectivity makes it invaluable for studies requiring lipolytic effects without the confounding variables of growth promotion, glucose alterations, or anabolic signalingallowing researchers to study fat metabolism in isolation
14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type 2 Diabetes Mellitus SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly
